Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC), a diversified biopharmaceutical company, is focused on discovering, developing, and commercializing innovative mechanism-targeted drugs to treat human cancers and other serious disorders. The company’s strategic goal is to discover and develop oral anticancer agents that target the cell cycle with the intent to slow the growth of tumors or even shrink their size while enhancing the patient’s quality of life. For further information, visit the Company’s web site at www.cyclacel.com.
- 17 years ago
QualityStocks
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – VolitionRx (NYSE American: VNRX) Prepares Reimbursement Submission for Nu.Q Cancer Assays in France
VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced that it is preparing a reimbursement submission for its Nu.Q®…
-
QualityStocksNewsBreaks – Brand Engagement Network Inc. (NASDAQ: BNAI) Reports Warrant Exercises, Debt Conversion, and Public Warrants Update
Brand Engagement Network Inc. (NASDAQ: BNAI) announced on Wednesday that it generated approximately $1.46 million…
-
Soligenix (NASDAQ: SNGX) Positioning for Impact in Growing Rare-Disease Landscape
The World Health Organization’s recent recognition of rare diseases as a global health priority underscores…